EUVIMEDEUVIMED entdecken
Crossref

A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment

Zheling Chen, Yu Cai, Keju Zhao, Anchen Qiu, Yanan Zhai, Shuting Jiang, Jingyi Pan, Peng Zhang, Hanchu Xiong, Qian Ye, Yunhua Liu, Liu Yang

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217934 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Zheling Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzho…. Hauptthemen laut MEDLINE: Oncolytic Viruses, Single-Domain Antibodies, CD47 Antigen, Pancreatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Key Research and Development Program of Zhejiang Province, National Natural Science Foundation of China, Zhejiang Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer remains a highly aggressive malignancy with limited treatment options. Recent advances have identified CD47 as a promising therapeutic target, though clinical translation faces challenges due to the complex immunosuppressive tumor microenvironment (TME). Here we developed an innovative oncolytic vaccinia virus platform expressing an anti-CD47 nanobody (OVV-aCD47nb), designed to simultaneously target tumor cells and modulate immune responses. Our in vitro studies demonstrated that OVV-aCD47nb effectively infected and replicated in pancreatic cancer cells while secreting functional aCD47nb that specifically bound to tumor cell surfaces. In vivo evaluation revealed remarkable therapeutic efficacy, with significant inhibition of primary tumor growth, suppression of contralateral and metastatic lesions, and substantial extension of survival in multiple pancreatic cancer models. Notably, the treatment induced robust and durable immune memory, providing protection against tumor rechallenge. At the mechanistic level, comprehensive analysis showed that OVV-aCD47nb induced profound remodeling of the TME, characterized by increased infiltration of cytotoxic CD8+ T cells, NK cells, and tumor-suppressive M1 macrophages. Through detailed T cell activation assays, we elucidated that virus-activated macrophages secreted key chemokines (CXCL9), creating a pro-inflammatory microenvironment that enhanced T cell recruitment and activation. Furthermore, the treatment upregulated PD-L1 expression in the TME, and combination therapy with PD-L1 blockade demonstrated synergistic anti-tumor effects, significantly improving survival outcomes. These findings establish OVV-aCD47nb as a multifaceted immunotherapeutic that reprograms the TME through coordinated immune activation. The macrophage-mediated T cell activation via chemokine signaling, combined with PD-L1 blockade, presents a transformative approach for pancreatic cancer with strong clinical potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirusesSingle-Domain AntibodiesCD47 AntigenPancreatic NeoplasmsOncolytic VirotherapyVaccinia virusTumor MicroenvironmentLymphocyte ActivationCell Line, TumorTumor EscapeImmunologic MemoryLymphocytes, Tumor-InfiltratingTumor-Associated MacrophagesCD8-Positive T-LymphocytesKiller Cells, NaturalChemokine CXCL9Xenograft Model Antitumor AssaysMice, Inbred C57BLHumansMaleAnimalsMice

Stichwörter der Autor:innen

CD47ImmunotherapyOncolytic virusPancreatic cancerTumor microenvironment

Substanzen

Single-Domain AntibodiesCD47 protein, humanCD47 AntigenCXCL9 protein, humanChemokine CXCL9

Autor:innen und Institutionen

  • Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China; School of Basic Medical Sciences, Hangzhou Normal…
  • Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China; School of Public Health, Hangzhou Medical College,…
  • Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China; Zhejiang Chinese Medical University, Hangzhou, Zhe…
  • Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Hangzhou Ronggu Biotechnology Co., LTD., China.

Förderung

  • Key Research and Development Program of Zhejiang Province
  • National Natural Science Foundation of China
  • Zhejiang Province Natural Science Foundation

Zitieren

APA

Chen, Z., Cai, Y., Zhao, K., Qiu, A., Zhai, Y., Jiang, S., Pan, J., Zhang, P., Xiong, H., Ye, Q., Liu, Y., & Yang, L. (2025). A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217934

Vancouver

Chen Z, Cai Y, Zhao K, Qiu A, Zhai Y, Jiang S, et al. A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217934

BibTeX
@article{Chen2025,
  author = {Chen, Zheling and Cai, Yu and Zhao, Keju and Qiu, Anchen and Zhai, Yanan and Jiang, Shuting and Pan, Jingyi and Zhang, Peng and Xiong, Hanchu and Ye, Qian and Liu, Yunhua and Yang, Liu},
  title = {A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217934}
}
Kostenlos starten →